Comparative Evaluation of Isoniazid and Rifampicin Dispersible Tablets Prepared by Direct Compression and Sublimation Methods
DOI:
https://doi.org/10.37285/ijpsn.2013.6.4.5Abstract
Dispersible tablets are gaining popularity over conventional tablets due to its increased popularity for administration to pediatric and geriatric patients as it provides quick onset of action and ease of administration. An attempt had been made, to develop dispersible tablet of isoniazid and rifampicin combination by direct compression and sublimation method, to increase the bioavailability of the anti-tubercular agents as well to provide the local delivery in the case of oral tuberculosis. Formulation F1 to F8 (2% and 4% w/w of different superdisintegrants (crospovidone, pregelatinized starch, croscarmellose sodium and sodium starch glycolate) formulated by direct compression method. The formulations containing 4% of superdisintegrants (F2, F4, F6, and F8) were selected as optimized and hence 4% of superdisintegrants were used for sublimation method (F9 to F12). The effects of sublimating material (camphor) on drug release profile and disintegration property were evaluated. Studies on two different methods showed sublimation method as a better alternative as its formulations rapidly disintegrates, disperse and shows faster drug release (in 14 min) in comparison to direct compression (in 20 min). Pre-compression parameters of formulation blends indicated good flow properties and compressibility. Simultaneous estimation was performed for calculation of drug content and % drug release. In vitro release data analysis revealed 90% drug release. F9 formulation (sublimation) showed best anti-tubercular activity. F2, F9 formulations were found to be stable even after 90 days. Hence it is evident from this study that fast dissolving tablets could be a promising delivery system for isoniazid and rifampicin with improved drug availability and better patient compliance.
Downloads
Metrics
Keywords:
Direct compression, sublimation, tuberculosis, superdisintegrants, anti-tubercular activity, simultaneous estimationDownloads
Published
How to Cite
Issue
Section
References
Amin S and Kohli K (2003). Stability studies. Indian Pharmacist: 11-12.
Bandari S, Mittapalli RK, Gannu R and Yamsani MR (2008). Orodispersible Tablets: An overview. Asian J Pharm 2(1): 2-11.
Cassano R, Trombino S , Ferrarelli T, Cavalcanti P, Giraldi C, Lai F, Loy G and Picci N (2012). Synthesis, characterization and in vitro anti-tubercular activity of isoniazid-gelatin conjugate. JPP 1-7.
Chang R, Guo X and Burnside B (2000). A review of fast dissolving tablets. Pharm. Tech. 52-54.
Chein YW (1992). Novel drug delivery systems. Marcel dekker inc. 2nd ed. New York, pp 139-140.
Coetzee N and Manomed, H (1996). Prevention of tuberculosis transmission in health care facilities. SAMJ 85(2): 115.
Franzblau SG, Witzig RS,Mclaughlin JC, Torres P, Madico G, Hernandez A, Degnan M, Cook MB, Quenzer VK,Ferguson RM and Gilman R (1998). Rapid.Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. JCM 36(2): 362-366.
Gerbino PP (2005). Remington: The science and practice of pharmacy (PA. Lippincott Williams & Wilkins). 21nd ed, Philadelphia pp 916-918.
Goyal P and Panday S (2002). Simultaneous spectrophotometric estimation of isoniazid and Rifampicin from combination dosage forms. Indian J. Pharma Sci 76-78.
Henry J (1993).The British medical association guide to medicines and drugs. Dorling Kindersley Inc. 2nd ed. London; 65, 66, 128, 292, 364.
Herfindal, TE, Gourle, DR and Hart LL (1992). Clinical pharmacy and therapeutics (Williams & Wilkins inc). 5th ed. Maryland, pp 1092-2008.
Hiremath P S and Saha N (2008). Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations. Int. J. Pharma 362: 118-225.
Indian pharmacopoeia (2007). Govt. of India: official Publication. volume I, pp 183-200.
Kakade RB, Kasture AV and Wadodkar SG (2002). Spectrophotometric determination of isoniazid and Rifampicin in pharmaceutical preparation. IJPS 64(1): 24-27.
Kochi A (1997). Is DOTS Health Breakthrough of the WHO Global TB Program, with responses from leading TB experts from the world. 18. No.3/4. WHO, Geneva, 1990; 1-12.
Kuchekar BS, Badhan AC and Mahajan HS (2003). Mouth Dissolving Tablets: A novel drug delivery system. Pharma Times 35: 10-17.
Kumar R, Patil M, Patil S, Paschapur M and Mahalaxmi R (2009). Development and Characterization of Orodispersible Tablets of Aceclofenac by Sublimation Technique. International Journal of PharmTech Research 1(2): 210-214.
Lachman L, Liberman HA and Kaing PL (1987). Tablets, The theory and practice of industrial pharmacy, 3rd indian edition, Bombay; Verghese publishing house pp 317-320.
Lourenço MCS, De Souza MVN, Pinheiro AC , Ferreira ML, Gonçalves RSB, Nogueira TCM and Peralta (2007). Evaluation of anti-tubercular activity of Nicotinic and isoniazid analogues. ARKIVOC (xv): 181-191.
Lucas T and Bishara RH (2004). A stability program for the distribution of drug products. Pharmaceutical Technology 68-73.
Mizumoto T, Masuda Y, Yamamoto T, Yanemochi E and Terada K (2005). Formulation design of a novel fast dissolving tablets. Int J Pharm 306: 83-90.
Mqoqi, Churchyard N, Kleinschmidt GA and Williams BG (1997). Attendance versus compliance with tuberculosis treatment in an occupational setting - a pilot study. SAMJ 87(11): 1517-1521.
Peto, RJ and Matthews TJE (1996). Tuberculosis control programme practical guideline, 1996-treatment regimens. SAMJ. 86(5): 560-561.
Piet M, Hooyamans and Robert J (1993). Drug research, Drug safety assessment in clinical trials. Edited by Gibert GS. Marcel Deccar inc 138: 83-91.
Schnidt P and Simone S (2002). Fast dispersible Ibuprofen tablets. Eur J Pharm Sci 15: 295-305.
Subramanyam CVS (2001). Textbook of Physical Pharmaceutics. Vallabh Prakashan, 2nd ed, pp 234-256.
Sudheendra, Udupi RH and Himabindu V (2012). Design, synthesis and biological evaluation of nitrogen heterocycles containing 4(3h) Quinazolinone and 1,2,4-triazole nuclei. IJPCS 1(1): 41-49.
United States Pharmacopoeia (2007). 30-National Formulary 25. pp 242, 378, 643, 731.
Yeola B, Pisal S, Paradkar A and Mahadik K (2000). New drug delivery system for Elderly. Indian Drugs 37(7): 312-18.